Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

Phase 3 Completed NCT02008357

Summary

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]).

Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score

Baseline, Week approximately 240 · score on a scale

Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score

Baseline, Week 336

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Brain Energy for Amyloid Transformation in Alzheimer's Disease Study — Wake Forest University Health Sciences
• Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
• Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
• Technology and Family Thriving Study — University of California, Santa Barbara
• Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation
• Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzhei — Georgetown University

All trials